| Schedule of Reconciliation Consolidated Net Loss |
The
following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the
Company’s consolidated net loss.
Schedule
of Reconciliation Consolidated Net Loss
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
Pharmaceuticals |
|
|
Computing Technology |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Product Cost of Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Gross Profit |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Administrative Expenses |
|
|
106,665 |
|
|
|
841,685 |
|
|
|
959,985 |
|
|
|
- |
|
| Research and Development Expenses |
|
|
18,948 |
|
|
|
1,545,513 |
|
|
|
491,586 |
|
|
|
- |
|
| Stock Based Compensation |
|
|
- |
|
|
|
84,636 |
|
|
|
58,606 |
|
|
|
- |
|
| Franchise Tax Expense |
|
|
21,940 |
|
|
|
- |
|
|
|
197,463 |
|
|
|
- |
|
| Warrant Issuance Expense |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Segment Net Loss |
|
|
147,553 |
|
|
|
2,471,834 |
|
|
|
1,707,640 |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconcilement of Net Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustments and Reconciling Items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dividends Paid on Series H Preferred Stock |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Interest and Dividend Income |
|
|
- |
|
|
|
62,512 |
|
|
|
71,340 |
|
|
|
- |
|
| Gain (Loss) on Sales of Marketable Securities |
|
|
- |
|
|
|
2,176 |
|
|
|
11,782 |
|
|
|
- |
|
| Unrealized Gain (Loss) on Marketable Securities |
|
|
- |
|
|
|
(1,597 |
) |
|
|
19,294 |
|
|
|
- |
|
| Change in Fair Value of Derivative Liabilities |
|
|
- |
|
|
|
1,284,000 |
|
|
|
510,000 |
|
|
|
- |
|
| Loss on FMV of Contingent Compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Casualty Gain/(Loss) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total Adjustments and Reconciling Items |
|
|
- |
|
|
|
1,347,091 |
|
|
|
612,416 |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consolidated Net Loss |
|
|
(147,553 |
) |
|
|
(1,124,743 |
) |
|
|
(1,095,224 |
) |
|
|
- |
|
|